Recordati Industria Chimica e Farmaceutica S.p.A. (RER1.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR

38.50

-0.02

(-0.05%)

At close: 09:15AM CEST

Advertisement

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Neutralpattern detected

All

Business Wire
Recordati Rare Diseases Announce Publication of Long-term Outcomes From the Extension to the Phase III LINC 3 Study of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease in the European Journal of Endocrinology
PUTEAUX, France, August 31, 2022--Recordati Rare Diseases announce today publication of the long-term outcomes from the open-label extension period of the Phase III LINC 3 study of Isturisa® in The European Journal of Endocrinology.1 These data support the long-term utility of Isturisa® in the maintenance treatment of patients with Cushing’s disease and reinforce Isturisa as an effective and well-tolerated oral therapy. Isturisa® is indicated in the EU for the treatment of adult patients with en

Advertisement